Ben Gil Price Insider Profile
4 Followers
Ben Gil Price, CEO and President at MetaVia, holds ― shares in MetaVia (Ticker: MTVA), holds 15.00K shares in Opus Genetics (Ticker: IRD), holds 37.33K shares in Sarepta Therapeutics (Ticker: SRPT). Most recently, Ben Gil Price ― shares of MetaVia on ― for an estimated value of ―.
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
+17.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Ben Gil Price holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Mar 16, 2016 - Mar 16, 2017
Return:+108.50%
The most profitable trade made by Ben Gil Price
Ben Gil Price's Trading History
MetaVia
―
CEO and President
―
―
Sarepta Therapeutics
Mar 16, 2016
Director
Informative Buy
75.11K
$771.61K
Opus Genetics
Jan 31, 2019
Director
Informative Buy
9.00K
$79.20K
List of latest transactions for each holding click on a transaction to see Ben Gil Price's performance on stock
You May Also Like
Ben Gil Price insider profile FAQ
What is the percentage of profitable transactions made by Ben Gil Price?
The percentage of profitable transactions made by Ben Gil Price is 50%.
What is the average return per transaction made by Ben Gil Price?
The average return per transaction made by Ben Gil Price is 17.50%.
What stocks does Ben Gil Price hold?
Ben Gil Price holds: MTVA, SRPT, IRD stocks.
What was Ben Gil Price’s latest transaction?
Ben Gil Price latest transaction was an Uninformative Buy of ―.
What was Ben Gil Price's most profitable transaction?
Ben Gil Price’s most profitable transaction was an Informative Buy of SRPT stock on March 16, 2016. The return on the trade was 108.50%.
What is Ben Gil Price's role in MetaVia?
Ben Gil Price's role in MetaVia is CEO and President.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.